Canada: Healthcare

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Life Sciences-Health Canada Takes Action Against Unauthorized Peptide Sales
On July 29, 2026, Health Canada announced that it had obtained a permanent injunction against a Québec-based company in connection with the sale of unauthorized injectable peptides in Canada. The announcement reflects Health Canada’s continued focus on peptide products and serves as a reminder that injectable peptides intended for human use are regulated as prescription drugs and are subject to Canada's drug regulatory framework.
Canada Healthcare
F
Fasken
Article
Health Canada Launches New Public Search Portal And Updated Guidance For Clinical Trials
Health Canada has launched a new public search portal for clinical trials authorized in Canada, alongside updated guidance documents for sponsors and applicants. The portal enhances transparency by making information about authorized clinical trials more readily accessible to patients, researchers, and industry stakeholders, while the updated guidance clarifies expectations for trial registration, summary results reporting, and public disclosure.
Canada Healthcare
TL
Torys LLP
Article
Public Service Bodies Beware: Why Reimbursements For Certain Contractual Employee Benefits May Not Qualify For GST/HST Rebates
The Federal Court of Appeal’s decision in IWK Health Centre v. Canada, 2026 FCA 113, confirms that employers cannot claim a GST/HST public service body rebate for employee reimbursements relating to personal healthcare services such as acupuncture, massage therapy, naturopathy, and homeopathy merely because the employer is contractually required to provide those benefits.
Canada Tax
RS
Rotfleisch & Samulovitch P.C.
Article
Omnipod Insulin Pumps Linked To Serious Health Risks, Potential For Diabetic Ketoacidosis
The Omnipod insulin pump system, a widely-used device for diabetes management, faces serious medical device recalls due to manufacturing defects that can compromise insulin delivery. These defects may lead to severe health complications including hyperglycemia and diabetic ketoacidosis, prompting legal investigations into potential claims against manufacturer Insulet Corporation. Canadian users of the recalled devices who have experienced serious health issues are urged to seek legal consultation regarding
Canada Healthcare
GP
Gluckstein Lawyers
Article
L’arrêté ministériel sur le recours autorisant Santé Canada à s’appuyer sur des décisions d’autorités réglementaires étrangères est maintenant en vigueur
Le 15 juillet 2026, l'Arrêté prévoyant le recours à des décisions d'autorités réglementaires étrangères de la ministre de la Santé est entré en vigueur, permettant à Santé Canada de s'appuyer sur des décisions d'autorités réglementaires étrangères de confiance pour accélérer l'examen des présentations de drogues.
Canada Healthcare
SB
Smart & Biggar
Article
The Supreme Court Clarifies Canada’s Methods Of Medical Treatment Doctrine
The Supreme Court of Canada has issued a landmark ruling clarifying when pharmaceutical innovations cross the line into unpatentable methods of medical treatment. In Pharmascience Inc. v. Janssen Inc., the Court established a new framework for assessing whether dosing regimens and treatment protocols constitute professional medical skill rather than patentable subject matter. This decision resolves decades of uncertainty surrounding the fixed-versus-variable dosage debate and provides clear guideposts for e
Canada IP
BL
Borden Ladner Gervais LLP
Article
Health Canada’s New Draft Guidance On Foreign Regulatory Reliance For Certain Drugs
Under the MRO, Health Canada may, in certain circumstances, rely on decisions or review documents produced by specified foreign regulatory authorities (“FRAs”) when reviewing eligible human and veterinary drug submissions. While Health Canada retains full authority for Canadian approval decisions, the framework introduces a mechanism through which portions of the review process can be deemed to have already been satisfied based on work performed by trusted international regulators.
Canada Healthcare
F
Fasken
Article
Cour suprême du Canada : les méthodes de traitement médical demeurent non brevetables, mais la validité du brevet de Janssen sur un schéma posologique de palipéridone est confirmée
La Cour suprême du Canada a rendu sa décision dans l'affaire Pharmascience Inc. c. Janssen Inc., 2026 CSC 26, concernant la brevetabilité des méthodes de traitement médical. La décision clarifie l'approche permettant de déterminer si une revendication constitue une méthode de traitement médical non brevetable, tout en confirmant la validité du brevet de Janssen sur un schéma posologique de palipéridone pour le traitement de la schizophrénie.
Canada IP
SB
Smart & Biggar
Article
Patentability And The Supreme Court: Conundrums Surrounding Methods Of Medical Treatment
The Supreme Court of Canada is poised to address a fundamental question in patent law: whether methods of medical treatment constitute patentable subject matter under the Patent Act. This analysis examines the statutory framework, historical precedents, and legislative changes that have shaped Canadian patent law's approach to medical innovations, particularly in light of the repeal of former restrictions and international trade agreements.
Canada IP
GW
Gowling WLG
See more

Highlighted Content

Latest Videos

See more